At baseline | After 18-month follow-up | |||
---|---|---|---|---|
1987 Criteria (n=47) | 2010 Criteria (n=87) | 1987 Criteria (n=96) | 2010 Criteria (n=92) | |
Age, years; median (IQR) | 60 (50–69) | 58 (46–68) | 60 (47–70) | 59 (45–68) |
Female; n (%) | 24 (51) | 53 (61) | 53 (55) | 56 (61) |
RF positive; n (%) | 26 (55) | 49 (56) | 44 (46) | 49 (53) |
Anti-CCP positive; n (%) | 28 (60) | 51 (59) | 48 (50) | 51 (55) |
Eventual outcome (after follow-up); n (%) | ||||
Definitive non-RA diagnosis | 3 (6) | 7 (8) | – | – |
Self-limiting illness | 5 (11) | 16 (18) | 12 (13) | 19 (21) |
DMARD use within first 18 months; n (%) | ||||
Methotrexate | 31 (66) | 50 (58) | 60 (63) | 51 (55) |
Other | 9 (19) | 15 (17) | 18 (19) | 16 (17) |
Anti-CCP, anticyclic citrullinated peptide antibody; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.